title: Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
abstract: A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m(2); oxaliplatin 80 mg/m(2); 5-FU 900 mg/m(2). The dose-limiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (alpha 0.05, CI+/-17). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (147 %).
authors.affiliation: IDI-Istituto Dermopatico dell'Immacolata, Rome, Italy.
authors.forename: M F
authors.initials: MF
authors.lastname: Morelli
authors.forename: A
authors.initials: A
authors.lastname: Santomaggio
authors.forename: E
authors.initials: E
authors.lastname: Ricevuto
authors.forename: K
authors.initials: K
authors.lastname: Cannita
authors.forename: F
authors.initials: F
authors.lastname: De Galitiis
authors.forename: M
authors.initials: M
authors.lastname: Tudini
authors.forename: G
authors.initials: G
authors.lastname: Bruera
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Pelliccione
authors.forename: F
authors.initials: F
authors.lastname: Calista
authors.forename: F
authors.initials: F
authors.lastname: Guglielmi
authors.forename: F
authors.initials: F
authors.lastname: Martella
authors.forename: P
authors.initials: P
authors.lastname: Lanfiuti Baldi
authors.forename: G
authors.initials: G
authors.lastname: Porzio
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: N
authors.initials: N
authors.lastname: Gebbia
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
authors.forename: P
authors.initials: P
authors.lastname: Marchetti
authors.forename: C
authors.initials: C
authors.lastname: Ficorella
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin